Statement from the International Diabetes Federation Related to Studies Published in Diabetelogia Suggesting Possible

* Reuters is not responsible for the content in this press release.

Mon Jun 29, 2009 8:12am EDT 

  BRUSSELS, BELGIUM, Jun 29 (MARKET WIRE) -- 
The International Diabetes Federation (IDF) today called for urgent
assessment and responses from regulatory authorities into a possible link
between the use of insulin glargine (an insulin analogue) and increased
risk of cancer based on findings published on 26 June, 2009 in
Diabetelogia, the journal of the European Association for the Study of
Diabetes (EASD).

    The online data published in Diabetelogia is based on four studies
relating to a possible link between a long-acting insulin analogue,
insulin glargine and cancer. According to EASD, the findings are based on
evidence from studies in Germany, Sweden, Scotland and the United
Kingdom. The studies however, are not conclusive.

    The International Diabetes Federation understands the concern about the
Diabetelogia study findings but urges the diabetes community to wait for
the current scientific information to be released and calls for urgent
further scientific studies to be undertaken in other countries.

    The International Diabetes Federation stresses that it is important that
people needing insulin do not stop taking the drug. IDF cautioned that
people with diabetes should see their doctor for advice before
considering any change to their treatment.

Contacts:
International Diabetes Federation
Kerrita McClaughlyn
Media Relations Manager
Office: +32-2-5431639 or Mobile: +32-487530625
media@idf.org

Copyright 2009, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.